Apogee Therapeutics (APGE) said Monday that interim phase 1 data for its APG333 antibody "exceeded trial objectives," demonstrating a half-life of about 55 days, supporting potential dosing every three and six months.
APG333, which is being developed for the treatment of inflammatory and immunology conditions, was also well tolerated across all cohorts, with doses of up to 1,000 mg, the company said.
Apogee shares were 2.7% higher in recent trading.
Price: 56.25, Change: +1.54, Percent Change: +2.81
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments